FUNDAMENTALS · Fundamentals · CA Healthcare

Xenon Pharmaceuticals (XENE) Fundamentals 2026 — Revenue Analysis | SniperIQ

Xenon Pharmaceuticals (XENE) is a CA-listed Healthcare company in Biotechnology with a market capitalization of $5.2B, trading at $66.31 on the NASDAQ. This SniperIQ fundamentals page covers Xenon Pharmaceuticals's valuation, profitability (net margin 0.0%), revenue ($8M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market Cap$5.2B
Net Margin0.0%
Revenue (FY25)$8M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is Xenon Pharmaceuticals's market cap?

Xenon Pharmaceuticals (XENE) has a market capitalization of approximately $5.2B, trading at $66.31 on the NASDAQ. Market cap moves with the live share price.

What is Xenon Pharmaceuticals's P/E ratio?

Xenon Pharmaceuticals's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 4.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is Xenon Pharmaceuticals?

Xenon Pharmaceuticals runs a net profit margin of 0.0%, a gross margin of 0.0%, and an operating margin of 0.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does Xenon Pharmaceuticals generate?

Xenon Pharmaceuticals reported revenue of $8M for fiscal year 2025, with net income of -

46M and earnings per share (EPS) of -4.36. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does Xenon Pharmaceuticals pay a dividend?

Xenon Pharmaceuticals does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is Xenon Pharmaceuticals financially healthy?

Xenon Pharmaceuticals carries a debt-to-equity ratio of 0.01x and a current ratio of 27.79x, with a market beta of 0.61. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is Xenon Pharmaceuticals a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Xenon Pharmaceuticals (XENE) the key facts are: market cap $5.2B, revenue $8M, 52-week range 30-72.66. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track Xenon Pharmaceuticals's full fundamentals live

Get Xenon Pharmaceuticals's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.